Sakar Healthcare Reports 42% YoY Revenue Growth in Q4FY26; EBITDA Rises 67%

Sakar Healthcare Reports 42% YoY Revenue Growth in Q4FY26; EBITDA Rises 67%​

Ahmedabad, May 12, 2026: Sakar Healthcare Ltd announced its audited financial results for the financial year ended March 31, 2026. The company, which operates a research-driven, API-integrated EU GMP approved oncology orals and injection manufacturing unit, posted strong growth across both the quarterly and annual results.

The financial performance for Q4FY26 showed significant acceleration, with Revenue from Operations reaching 7,109.70 lakhs. This marks a 42% year-over-year (YoY) increase, reflecting strong demand and new market authorizations for the company's oncology products.

Consolidated Financial Performance Highlights​

Sakar Healthcare’s consolidated financial data reveals robust growth across the period. The following table details the key financial metrics for Q4FY26 and the full fiscal year 2026.

Operational Achievements​

Beyond the financial results, Sakar Healthcare noted significant operational milestones. The company completed over 60 business contracts involving oncology products, with more than 35 discussions currently ongoing.

Globally, 125 dossiers were submitted out of 250 shared, and 12 of these dossiers successfully received Marketing Authorizations from regulatory authorities. Furthermore, the company shared 32 developed oncology product dossiers, of which 21 were reported, resulting in 11 approvals (including Abiraterone-1, Imatinib-1, Tamoxifen-1, Capecitabine-1, Gemcitabine-2, Carboplatin-3, Irinotecan-1, and Docetaxel-2).

Technology Transfer projects for oncology products are also proceeding with Accord-Intas, Torrent-UK & Germany, Emcure, Glenmark, and Zydus. Out of these, four sites have received variation approvals (two each in the UK and EU).

Management Commentary​

Mr. Sanjay Shah, Managing Director, commented on the results, stating that Q4 marked a meaningful step forward for Sakar Healthcare. He attributed the strong year-on-year growth and improved profitability to steady execution across the business.

Shah highlighted the increasing importance of oncology in the company’s overall growth strategy. He noted that the oncology platform is well-positioned to benefit from rising volumes, improving market reach, and operating leverage as scale improves. The company believes that as approvals continue to convert into commercial supplies, the business is entering a stronger and more sustainable growth phase.

Sakar Healthcare Limited is a publicly listed pharmaceutical manufacturer and exporter established in 2004, specializing in oncology, antibiotics, and general formulations. The company operates world-class, EU-GMP and WHO-GMP certified facilities and maintains a global presence across more than 60 countries, serving international pharmaceutical companies through CDMO, CRAMS, and technology transfer collaborations.

SAKAR Stock Price Movement​

Shares of SAKAR HEALTHCARE LIMITED are edging higher to ₹572.5 as of 9:16 AM, gaining 0.50% or ₹2.85 in live trading. The stock continues its upward momentum on a current volume of 1,663 shares.